In this context, the authors warrant clinical and pre-clinical investigations to assess the feasibility of a PSMA-targeted theragnostic approach in ccRCC patients and to evaluate its safety and efficacy. The gene discussed is FOLH1; the disease is nonpapillary renal cell carcinoma.